Veteran’s Prostate Cancer Treatment and Research Act
Latest action (22 Sep 2020): On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
What this bill does
**H.R. 6092 — Veteran's Prostate Cancer Treatment and Research Act**
This bill would direct the Secretary of Veterans Affairs to create a national clinical pathway for prostate cancer within the VA's National Surgery Office, covering care from early detection through end-of-life treatment. The pathway would include a multi-disciplinary care plan involving both VA and community providers, suggested (non-mandatory) screening and treatment protocols for higher-risk groups, and would require public comment before finalization. The VA would also have to submit to Congress a plan for a comprehensive, multidisciplinary prostate cancer care program with quarterly public quality reports, electronic decision-support tools, and patient/provider education. Additionally, the bill calls for continued funding of prostate cancer research and creation of a national, real-time prostate cancer patient registry to support treatment tracking, research, and clinical trials.
The bill primarily affects veterans receiving VA care, particularly those at elevated risk of prostate cancer, such as those exposed to herbicides like Agent Orange. It also affects VA clinical staff, administrators, and researchers, who would be required to implement new protocols, reporting systems, and data-sharing tools, and would involve coordination with agencies like the NIH, CDC, FDA, and CMS.
The bill passed the House by voice vote on September 22, 2020, but was not taken up or passed by the Senate before that Congress ended, so it did not become law.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Official summary
Veteran's Prostate Cancer Treatment and Research Act
This bill requires the Department of Veterans Affairs (VA) to implement programs and resources related to the diagnosis and treatment of prostate cancer.
Specifically, the bill requires the VA to establish in its National Surgery Office a national clinical pathway for all stages of prostate cancer that includes specified elements. A clinical pathway is a health care management tool designed around research and evidence-backed practices that provides direction for the clinical care and treatment of a specific episode of a condition or ailment.
The VA must publish the proposed clinical pathway in the Federal Register for public comment. Additionally, the bill requires the VA to publish the established clinical pathway on a public VA website and to update the clinical pathway at least annually.
Under the bill, the VA must submit (1) a plan to establish a comprehensive prostate cancer program, and (2) a plan that provides for continual funding for supporting prostate cancer research through the VA Office of Research and Development. The VA must also establish a program evaluation tool to learn best practices of multidisciplinary disease-based implementation.
Finally, the VA must establish a real-time, actionable, national prostate cancer registry that is accessible to clinicians and researchers.
Timeline
22 Sep 2020
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
17 Sep 2020
Ordered to be Reported by Voice Vote.
Common questions
- What does H.R. 6092 do?
- **H.R. 6092 — Veteran's Prostate Cancer Treatment and Research Act** This bill would direct the Secretary of Veterans Affairs to create a national clinical pathway for prostate cancer within the VA's National Surgery Office, covering care from early detection through end-of-life treatment. The pathway would include a multi-disciplinary care plan involving both VA and community providers, suggested (non-mandatory) screening and treatment protocols for higher-risk groups, and would require public comment before finalization. The VA would also have to submit to Congress a plan for a comprehensive, multidisciplinary prostate cancer care program with quarterly public quality reports, electronic decision-support tools, and patient/provider education. Additionally, the bill calls for continued funding of prostate cancer research and creation of a national, real-time prostate cancer patient registry to support treatment tracking, research, and clinical trials. The bill primarily affects veterans receiving VA care, particularly those at elevated risk of prostate cancer, such as those exposed to herbicides like Agent Orange. It also affects VA clinical staff, administrators, and researchers, who would be required to implement new protocols, reporting systems, and data-sharing tools, and would involve coordination with agencies like the NIH, CDC, FDA, and CMS. The bill passed the House by voice vote on September 22, 2020, but was not taken up or passed by the Senate before that Congress ended, so it did not become law.
- Has H.R. 6092 become law?
- Not yet. As of 22 Sep 2020, H.R. 6092 is passed house (senate next).
- Who sponsored H.R. 6092?
- H.R. 6092 was sponsored by Rep. Neal Dunn [R-FL2] (Republican-FL), with 3 cosponsors.
- What's the latest action on H.R. 6092?
- On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (22 Sep 2020).
Related bills in Armed Forces and National Security
Minuteman III Health and Safety Act
Expressing the sense of the House of Representatives that the third Friday of September should be recognized as “National POW/MIA Recognition Day”.
Bone Marrow Radiation Shielding Act
Medal of Honor Access and Liaison Act
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.